Principal Financial Group
TSHA icon

Principal Financial Group’s Taysha Gene Therapies TSHA Stock Holding History

Principal Financial Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$72.3K Buy
16,185
+3,362
+26% +$15.6K ﹤0.01% 2134
2025
Q4 		$70.5K Sell
12,823
-3,428
-21% -$16.6K ﹤0.01% 2156
2025
Q3 		$53.1K Buy
16,251
+4,091
+34% +$11.6K ﹤0.01% 2212
2025
Q2 		$28.1K Sell
12,160
-1,829
-13% -$3.97K ﹤0.01% 2205
2025
Q1 		$19.4K Sell
13,989
-982
-7% -$1.64K ﹤0.01% 2148
2024
Q4 		$25.9K Sell
14,971
-828
-5% -$1.72K ﹤0.01% 2192
2024
Q3 		$31.8K Sell
15,799
-5,810
-27% -$12.7K ﹤0.01% 2196
2024
Q2 		$48.4K Buy
+21,609
New +$62.9K ﹤0.01% 2287

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Principal Financial Group's TSHA Position: Q1 2026 in Review

Principal Financial Group increased its Taysha Gene Therapies (TSHA) stake by 26% in Q1 2026, buying an estimated $15.6K and bringing the position to 16,185 shares worth $72.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2134.

Principal Financial Group first reported a position in TSHA in Q2 2024 and has held it in 8 quarters since. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Principal Financial Group held 16,185 shares of Taysha Gene Therapies worth $72.3K as of Q1 2026.
  • Principal Financial Group bought 3,362 Taysha Gene Therapies shares in Q1 2026, an estimated $15.6K.
  • Taysha Gene Therapies made up ﹤0.01% of Principal Financial Group's portfolio in Q1 2026, its #2134 holding.
  • Principal Financial Group first reported a position in Taysha Gene Therapies in Q2 2024 and has held it in 8 quarters since.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Principal Financial Group's 13F filing for Q1 2026, filed 4 May 2026.